Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Breast Cancer
Phase NA
Enrollment 595
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates whether radiotherapy can safely be omitted in breast cancer patients with T1-2N0 tumors who achieve a pathologic complete response after neoadjuvant systemic therapy and breast-conserving surgery

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Omission of radiotherapy — Omission of radiotherapy

Primary Outcomes

  • Local recurrence (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-07
Completion: 2037-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 595 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Netherlands Cancer Institute
Collaborators: Dutch Cancer Society, Borstkanker Onderzoek Groep
Contact Information
Study Contact:
F.H. van Duijnhoven, MD, PhD
+31(0)20 5126170
f.v.duijnhoven@nki.nl
J.P. van Olmen, Drs
020-5129111
j.v.olmen@nki.nl
F.H. van Duijnhoven, MD, PhD
+31(0)20 5126170
f.v.duijnhoven@nki.nl
Antoni van Leeuwenhoek
Interventions
  • Radiation: Omission of radiotherapy — Omission of radiotherapy
Study Locations (1 sites)
Antoni van Leeuwenhoek, Amsterdam, North Holland 1066 CX Netherlands
Eligibility Criteria
Inclusion Criteria: * Women, aged ≥ 18 years * Invasive HR positive/Her2 negative, Her2+ (ER/PR +/-) or TN breast cancer * Concurrent DCIS in pre-NST biopsy is allowed if there is no suspicion of extensive component i.e. absence of non-mass enhancement on pre-NST MRI, contrast-enhanced mammography or breast-specific gamma imaging and/or absence of calcifications on pre-NST mammography * Primary tumour (T) clinical stage cT1-2 * Unifocal disease; confirmed by pre-NST MRI, contrast-enhanced mammography or breast-specific gamma imaging * Clinical nodal stage 0; absence of lymph node metastases should be confirmed by ultrasound or FDG-PET/CT * Neoadjuvant systemic treatment (NST) * Marker placed in breast tumour prior to NST * Breast conserving surgery performed, i.e. no mastectomy * Sentinel node biopsy performed before or after NST * Pathologic complete response in breast and lymph nodes, i.e. no residual tumour cells or DCIS detected * Written informed consent Exclusion Criteria: * Primary tumour (T) clinical stage cT3-4 * Pre- or post-NST diagnosis of nodal disease including isolated tumour cells * Patients without axillary ultrasound or FDG-PET/CT pre-NST * History of breast cancer or DCIS * Synchronous contralateral breast cancer or DCIS * Synchronous M1 disease * Carrier of gene mutation associated with increased risk of breast cancer, i.e. BRCA1, BRCA2, CHEK2, TP53 or PALB-2
Conditions Obesity, Overweight, Chronic Weight Mana...
Phase PHASE3
Enrollment 1100
Locations 74 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: aleniglipron — Drug: aleniglipron administered orally
  • Drug: aleniglipron — Drug: aleniglipron administered orally
  • Drug: aleniglipron — Drug: aleniglipron administered orally
  • Drug: Placebo — Drug: placebo administered orally

Primary Outcomes

  • Percent change in body weight from Baseline (Baseline and week 76)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-17
Completion: 2028-11
Eligibility
Age: 18 Years – 79 Years
Sex: ALL
Volunteers: true
Enrollment: 1100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Contact Information
Study Contact:
Medical Director
1-650-457-1959
GSBRClinicalTrials@structuretx.com
Medical Director
GSBRClinicalTrials@structuretx.com
ACCOMPLISH-2 Research Site
Medical Director
GSBRClinicalTrials@structuretx.com
ACCOMPLISH-2 Research Site
Interventions
  • Drug: aleniglipron — Drug: aleniglipron administered orally
  • Drug: aleniglipron — Drug: aleniglipron administered orally
  • Drug: aleniglipron — Drug: aleniglipron administered orally
  • Drug: Placebo — Drug: placebo administered orally
Study Locations (74 sites)
ACCOMPLISH-2 Research Site, Birmingham, Alabama 35242 United States
ACCOMPLISH-2 Research Site, Chandler, Arizona 85225 United States
ACCOMPLISH-2 Research Site, Phoenix, Arizona 85028 United States
ACCOMPLISH-2 Research Site, Sun City West, Arizona 85375 United States
ACCOMPLISH-2 Research Site, Tucson, Arizona 85741 United States
ACCOMPLISH-2 Research Site, Little Rock, Arkansas 72211 United States
ACCOMPLISH-2 Research Site, Escondido, California 92025 United States
ACCOMPLISH-2 Research Site, Fountain Valley, California 92708 United States
ACCOMPLISH-2 Research Site, La Jolla, California 92123 United States
ACCOMPLISH-2 Research Site, Lake Forest, California 92630 United States
Eligibility Criteria
Inclusion Criteria: * Signed Informed Consent * Have a BMI ≥27.0 kg/m2 at Screening * Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening Exclusion Criteria: * Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM. * Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening. * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Self-reported change in body weight \>5 kg (11 pounds) within 3 months before Screening. * Have prior or planned surgical or non-surgical treatment for obesity.
Conditions Type 2 Diabetes Mellitus (T2DM), Metabol...
Phase Not Applicable
Enrollment 2720
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: Observational — Observational

Primary Outcomes

  • Incidence of onset T2DM (through study completion, an average of 3 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-01
Completion: 2025-12-31
Eligibility
Age: 20 Years – 90 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 2720 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ningbo No. 1 Hospital
Contact Information
Study Contact:
Lei Xu
+8613486659126
xulei22@163.com
Lei Xu, MD
+8613486659126
xulei22@163.com
the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000
Interventions
  • Other: Observational — Observational
Study Locations (1 sites)
the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000, Ningbo, Zhejiang 315000 China
Eligibility Criteria
Inclusion Criteria: 1. Abdominal ultrasound data available in annual health check-up records 2. At least one of the following five metabolic indicators recorded annually: (1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein cholesterol (HDL-C) (5) Fasting plasma glucose or glycated hemoglobin (HbA1c) Exclusion Criteria: 1. Age \<20 or \>90 years 2. Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection) 3. Type 2 diabetes mellitus at baseline 4. Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)
Conditions Type 2 Diabetic Patients, T2DM (Type 2 D...
Phase NA
Enrollment 115
Locations 16 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Beinaglutide — Beinaglutide (continuous subcutaneous infusion)
  • Drug: Insulin aspart — Insulin aspart (CSII)

Primary Outcomes

  • The proportion of subjects achieving HbA1c <7.0%, no weight increase (≤0 kg), and no hypoglycemia (blood glucose ≤3.9 mmol/L or severe hypoglycemia) after 8 weeks of treatment. (From baseline to the end of treatment at 8 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-07-02
Completion: 2025-12
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 115 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Hospital
Contact Information
Study Contact:
Lixin Guo, M.D.,Ph.D.
+8613901317569
glx1218@163.com
Dongni Yu, M.D.
+8613621273587
yudongni@outlook.com
Yufeng Li, M.D.
+8613911080328
doctorlyf@126.com
Pinggu District Hospital
Interventions
  • Drug: Beinaglutide — Beinaglutide (continuous subcutaneous infusion)
  • Drug: Insulin aspart — Insulin aspart (CSII)
Study Locations (16 sites)
Pinggu District Hospital, Beijing, Beijing Municipality 000 China
Capital Medical University Beijing Anzhen Hospital, Beijing, Beijing Municipality China
Emergency General Hospital, Beijing, Beijing Municipality China
Peking University Shougang Hospital, Beijing, Beijing Municipality China
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong 000 China
Harbin Medical University Second Hospital, Harbin, Heilongjiang China
Southeast University Zhongda Hospital, Nanjing, Jiangsu 000 China
Xuzhou Medical University Affiliated Hospital, Xuzhou, Jiangsu China
China-Japan Union Hospital of Jilin University, Changchun, Jilin China
Jilin University Second Hospital, Changchun, Jilin China
Eligibility Criteria
Inclusion Criteria: 1. Age 18 to 70 years (inclusive) at enrollment, regardless of gender. 2. Voluntary signing of the informed consent form. 3. Newly diagnosed type 2 diabetes mellitus patients, diagnosed according to the WHO 1999 criteria, with a disease duration ≤1 year. 4. HbA1c between 7.5% and 10.0%. 5. BMI between 24 kg/m² and 42 kg/m². 6. Subjects who have not taken antidiabetic medications or have used oral antidiabetic medications for less than 3 months and have discontinued for more than 1 month (calculated from the date of signing the informed consent form). 7. Subjects with reproductive potential (including male subjects whose partners have reproductive potential) agree to use effective contraception during the study and for 1 month after study completion. Exclusion Criteria: 1. Patients with type 1 diabetes or other types of diabetes. 2. History of obstructive intestinal diseases or potential complications: subjects with post-abdominal surgery or peritoneal infection-related intestinal adhesions, intestinal obstruction sequelae; subjects with intestinal motility disorders, chronic constipation; subjects with a history of Crohn's disease or ulcerative colitis. 3. History of pancreatitis. 4. Family history of medullary thyroid carcinoma. 5. History of malignant tumors. 6. ALT, AST \>3 times the upper limit of normal, and/or total bilirubin \>2 times the upper limit of normal. 7. Moderate to severe renal insufficiency (eGFR \<60 ml/min/1.73m²). 8. Triglycerides ≥5.0 mmol/L. 9. Multiple endocrine neoplasia type 2 (MEN 2). 10. Participation in any pre-marketing drug study within 3 months. 11. Use or expected use of systemic corticosteroids, immunosuppressants, or cytotoxic drugs during the study period. 12. History of diabetic ketoacidosis or non-ketotic hyperosmolar coma within 6 months prior to screening. 13. Blood pressure exceeding the following criteria (untreated or treated): systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg. 14. History of any of the following cardiovascular diseases within 3 months prior to screening: acute myocardial infarction, New York Heart Association functional class III/IV heart failure or left ventricular ejection fraction ≤40%, or cerebrovascular event (stroke). 15. Allergy to binaclotide or any component of the study drug, or allergy to insulin or any component of the insulin used in the study. 16. Presence of other severe diseases that may interfere with the study, as judged by the investigator. 17. Pregnant or breastfeeding women. 18. Poor compliance, as judged by the investigator, and inability to complete the study as required. 19. Inability to undergo continuous pump infusion: subjects allergic to subcutaneous infusion tubes or adhesive tape; subjects unwilling to have long-term subcutaneous infusion tubes or continuous pump use; subjects with psychological aversion to pump therapy; subjects or their families lack relevant knowledge and are unable to master the use after training; subjects with severe psychological disorders or mental abnormalities; subjects who are unable to care for themselves and have no caregivers. 20. Any other factors deemed unsuitable for participation in the study by the investigator.
Conditions Type 2 Diabetes
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the Impact of Continuous Glucose Monitoring Academy Education Curriculum Versus Standard Care on Glycemic Outcomes for Youth With Type 2 Diabetes (T2D): * The first aim is to determine how feasible it is to adapt the Continuous Glucose Monitoring Academy curriculum to teach youth with T2D glucose management strategies. * The second aim is to evaluate the effects of the Continuous Glucose Monitoring Academy metrics. * The third aim is to explore the relationships between these metrics with diabetes distress, diabetes family responsibilities, and process metrics. Participants will join for a total of four weeks of education, followed by a six-month clinical review. They will have access to an online workbook and videos, and will participate in virtual sessions with a diabetes educator who will cover glucose management strategies in-depth. Participants will wear their preferred Continuous Glucose Monitoring system (Dexcom or FreeStyle Libre) provided via insurance and inserted at the baseline visit.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Continuous Glucose Monitoring Academy — Educational materials as well as online sessions with diabetes educators.
  • Behavioral: Standard Education — Standard of care receives general education about diabetes.

Primary Outcomes

  • Mean change in Time in Range (TIR) from baseline to 6 months (Baseline to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-23
Completion: 2026-12-30
Eligibility
Age: 8 Years – 21 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Los Angeles
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Rebecca Barber, PhD, RN (PRINCIPAL_INVESTIGATOR) - Children's Hospital Los Angeles
Contact Information
Study Contact:
Natalia Garban
3233611359
ngarban@chla.usc.edu
Rebecca Barber
3233611359
rbarber@chla.usc.edu
Natalia Garban
ngarban@chla.usc.edu
Children's Hospital Los Angeles
Interventions
  • Behavioral: Continuous Glucose Monitoring Academy — Educational materials as well as online sessions with diabetes educators.
  • Behavioral: Standard Education — Standard of care receives general education about diabetes.
Study Locations (1 sites)
Children's Hospital Los Angeles, Los Angeles, California 90027 United States
Eligibility Criteria
Inclusion Criteria: 1. Current age of 8-21 years; 2. T2D diagnosis; 3. Able to speak, read, and write English or Spanish Exclusion Criteria: a. Known history of medical adhesive allergies;
Conditions Diabetes Mellitus, Type 2, Obesity, Morb...
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to perform a detailed description of the feno- and genotype of people living with type 2 diabetes and severe obesity who are linked to care at Steno Diabetes Center Greenland. The main questions it aims to answer are: * Are monogenetic diabetes variants associated with the same risk of developing late diabetic complications as other types of diabetes? * Can genotyping and thereby personalized medicine be implemented in Greenland, and can personalized medicine lead to improved treatment? * What is the prevalence of sleep apnea among high-risk individuals in Greenland? * Is it possible to develop and implement a simple algorithm for the identification of sleep apnea in Greenland that can ensure treatment of severe sleep apnea? Participants will: * Answer WHO-5 and FOSQ-10 questionnaires regarding quality of life and functional outcomes of sleepiness * Perform VAGUS examinations for Cardiovasculare Autonomic Neuropathy * Clinical examination of height, weight, circumference of hip, waist and neck, Friedman tonsil and tongue score, nasal air flow, nasal septal deviation * Blood samples for full genome sequencing

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Genetic: Whole genome sequencing — Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
  • Diagnostic Test: VAGUS — To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
  • Diagnostic Test: NightOwl — Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.
  • Device: CPAP — Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).

Primary Outcomes

  • Number of participants with MODY diabetes and their complication status (Blood drawn at inclusion. Results for participants ready after approximately 6 months.)
  • Number of participants with diabetic complication (Types and number of complications are available at inclusion. No follow-up screenings for complications are performed.)
  • Number of participants with obstructive sleep apnea (Home sleep testing is performed for 3 nights after inclusion. Confirmatory home sleep examinations performed one day after the initial sleep examination. In total, four days examinations time.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-07-15
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Steno Diabetes Center Greenland
Collaborators: Zealand University Hospital, University of Copenhagen
Principal Investigators:
  • Marit Eika Jørgensen, Md. Phd (PRINCIPAL_INVESTIGATOR) - Steno Diabetes Center Greenland
Contact Information
Study Contact:
Mads Jensen, MD.
+299 34 46 23
MMSN@peqqik.gl
Marit Eika Jørgensen, MD. Ph.d
+299 34 43 24
MAEJ@peqqik.gl
Mads Mose Jensen, MD.
+299 34 46 23
MMSN@peqqik.gl
Steno Diabetes Center Greenland, Queen Ingrids Hospital
Interventions
  • Genetic: Whole genome sequencing — Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
  • Diagnostic Test: VAGUS — To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
  • Diagnostic Test: NightOwl — Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.
  • Device: CPAP — Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
Study Locations (1 sites)
Steno Diabetes Center Greenland, Queen Ingrids Hospital, Nuuk, Sermersooq 3900 Greenland
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes and/or morbid obesity (BMI \>40) * Over 18 years old Exclusion Criteria: * Does not speak either English, Danish or Greenlandic
Conditions Diabetes Mellitus, Type 2, End Stage Ren...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Pro-inflammatory cytokines, which are elevated in pro-inflammatory disease states (e.g., type II diabetes mellitus \[T2DM\], irritable bowel diseases \[IBD\], and end stage renal disease \[ESRD\]) have been shown to inhibit hepatic drug-metabolizing enzymes, including members of the cytochrome P450 (CYP) family, and drug transporters; resultantly, pro-inflammatory diseases have been demonstrated to increase the exposure and potential for adverse drug events with co-administered CYP and drug transporter substrates. However, the clinical relevance of pro-inflammatory disease-drug interactions has not been systematically evaluated. The long-term goal of this research is to establish clinical strategies to mitigate pro-inflammatory disease-drug interactions and associated adverse drug events. The specific objective of this study is to determine the clinical relevance of pro-inflammatory disease-drug interactions, including establishment of the effect of pro-inflammatory diseases on drug disposition throughout disease trajectories (i.e., determining the differential effects on drug disposition based on the severity of disease). Towards this objective, this study will investigate the extent of increases in inflammation in patients with varying severities of pro-inflammatory diseases and estimate the resulting effects on drug disposition. Cytokine/chemokine concentrations and immune cell profiles will be assayed from blood samples of adult and pediatric patients with differing severities of pro-inflammatory diseases, using established disease monitoring parameters (e.g., glycosylated hemoglobin \[HbA1C\] for T2DM, C-reactive protein \[CRP\] for IBD, proteinuria for ESRD). The effect of changes in inflammation during differing severities of these pro-inflammatory diseases on drug disposition will then be estimated using established pharmacokinetic modeling approaches (e.g., physiologically-based pharmacokinetic modeling \[PBPK\]).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: None (Observational) — This observational study will not involve any interventions. Instead, the study will collect blood samples at one or multiple time points.

Primary Outcomes

  • Quantification of Plasma Cytokine Concentrations (Through study completion, up to 2 years post enrollment)
  • Phenotyping of Patient Immune Cells (Through study completion, up to 2 years post enrollment)
  • Quantification of the Plasma Concentrations of Endogenous Biomarkers of Drug Metabolism and Transport (Through study completion, up to 2 years post enrollment)
  • Measures of Inflammatory Disease Severity (Through study completion, up to 2 years post enrollment)
  • Development of Adverse Events Attributable to CYP/Transporter Substrate Medications (Through study completion, up to 2 years post enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-01
Completion: 2030-12-31
Eligibility
Age: 12 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Indiana University
Contact Information
Study Contact:
Ross C Robinson
3172742744
rossrobi@iu.edu
Tyler A Shugg, PharmD, PhD
9856304594
tshugg@iu.edu
Ross Robinson
3172742744
rossrobi@iu.edu
Indiana University Hospital
Interventions
  • Other: None (Observational) — This observational study will not involve any interventions. Instead, the study will collect blood samples at one or multiple time points.
Study Locations (1 sites)
Indiana University Hospital, Indianapolis, Indiana 46202 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosed with a pro-inflammatory disease, including T2DM, IBD, and ESRD * Ability to provide written informed consent and HIPAA authorization Exclusion Criteria: * Diagnosis or past medical history of non-IBD autoimmune disorder, including systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis * Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion) * Concomitant treatment with systemic immunosuppressant drugs
Conditions Type 2 Diabetes
Phase PHASE3
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, randomized, double-blind, placebo-controlled , phase 3 clinical trial aimed at evaluating the efficacy and safety of HDM1005 versus placebo in subjects with T2DM inadequate glycemic control with diet and exercise alone. A total of 240 subjects will be enrolled. All subjects will be stratified by baseline HbA1c levels (≤8.5% or \>8.5%) , then randomized 1:1:1 to: Group 1 (HDM1005), Group 2 (HDM1005), and Group 3 (placebo), with 80 subjects in each treatment group. At week 36, subjects in placebo group will receive HDM1005 injection until week 52. All treatment groups will implement dose titration to achieve the target dose. The study consists of: up to 2-week screening, 2-week run-in, 36-week core treatment, 16-week extension treatment, and 4-week follow-up, totaling 60 weeks. The end-of-study visit will be conducted 28 days after the last administration cycle.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: HDM1005 1 — administered SC, QW, 52 weeks.
  • Drug: HDM1005 2 — administered SC, QW, 52 weeks.
  • Drug: HDM1005 injection or placebo — administered SC, QW, 52 weeks.

Primary Outcomes

  • Change from baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 36)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-02-24
Completion: 2027-12-17
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Wenyan Cao
+86 18810614389
cxycaowenyan@eastchinapharm.com
Yiming Mu
+86 13910580089
muyiming@301hospital.com.cn
Chinese PLA General Hospital
Interventions
  • Drug: HDM1005 1 — administered SC, QW, 52 weeks.
  • Drug: HDM1005 2 — administered SC, QW, 52 weeks.
  • Drug: HDM1005 injection or placebo — administered SC, QW, 52 weeks.
Study Locations (1 sites)
Chinese PLA General Hospital, Beijing, China
Eligibility Criteria
Inclusion Criteria: 1. Confirmed as Type 2 Diabetes Mellitus (T2DM) for at least 12 weeks and have not used any antihyperglycemic medications during for at least 12 weeks prior to screening. 2. Hemoglobin A1c (HbA1c) ≥7.5% and ≤10.5% at screening; and ≥7.0% and ≤10.5% at randomization. 3. Body Mass Index (BMI) ≥22.5 kg/m2. Exclusion Criteria: 1. Other types of diabetes besides T2DM. 2. Acute complications of diabetes (such as diabetic ketoacidosis, diabetic lactic acidosis, or hyperosmolar non-ketoticcoma) occurred within 24 weeks prior to signing the Informed Consent Form (ICF). 3. History of a level 3 hypoglycemic episode or a history of asymptomatic hypoglycemic episodes within 24 weeks prior to signing the ICF. 4. History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2). 5. History of acute or chronic pancreatitis; or presence of risk factors for pancreatitis; or history of symptomatic gallbladder disease requiring treatment per investigator's assessment within 24 weeks prior to signing the ICF. 6. Investigator determines that the subject has a condition or disease affecting gastric emptying or gastrointestinal nutrient absorption, such as weight-loss surgery or other gastric resections, irritable bowel syndrome, dyspepsia, or gastroparesis. 7. Use of any antidiabetic medications within 12 weeks prior to signing the ICF; excluding short-term insulin use (cumulative duration ≤7 days) for concomitant illness, stress, or perioperative periods. 8. Hemoglobin (Hb) \<100 g/L (female) or \<110 g/L (male). 9. FPG ≥13.9 mmol/L. 10. Aspartate aminotransferase (AST) \>3× upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3× ULN. 11. Total bilirubin \>1.5× ULN. 12. Fasting triglyceride (TG) \>5.6 mmol/L (500 mg/dL).
Conditions Diabetes Mellitus, Type 2, PreDiabetes, ...
Phase NA
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes. Additionally, direct insulin sensitivity testing, and radiological measurement of visceral fat and intrahepatic fat content is measured at three timepoints to correlate clinical indices with cellular changes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Dietary Intervention Mediterranean Low Carbohydrate Diet — Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
  • Behavioral: Dietary Intervention Standard Low Carbohydrate Diet — Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
  • Behavioral: Dietary Intervention Standard Low Fat Diet — Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.

Primary Outcomes

  • Change from baseline on the 2-stage Steady State Plasma Glucose test (Peak weight (4 weeks))
  • Change from baseline on the radiographic measurement of visceral to subcutaneous (V:S) fat ratio (Peak weight (4 weeks))
  • Change from baseline on the magnetic-resonance based measurement of intrahepatic lipid deposition (Peak weight (4 weeks))
  • Change from peak weight on the 2-stage Steady State Plasma Glucose test (Post-weight loss (8 weeks))
  • Change from baseline on the radiographic measurement of visceral to subcutaneous (V:S) fat ratio (Post-weight loss (8 weeks))
  • Change from baseline on the magnetic-resonance based measurement of intrahepatic lipid deposition (Post-weight loss (8 weeks))
  • Measurement of markers of lipid and carbohydrate metabolism and inflammation from adipose mRNA (Baseline)
  • Quantification of plasma inflammatory cytokine levels in serum samples by Luminex immunoassay (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2019-01-31
Completion: 2026-12-30
Eligibility
Age: 35 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Tracey McLaughlin, MD (PRINCIPAL_INVESTIGATOR) - Stanford University, Department of Medicine, Division of Endocrinology
Contact Information
Study Contact:
Ekrem M Ayhan, BS
908-619-5381
ayhane@stanford.edu
Dalia Perelman, MS, RD
daliap@stanford.edu
Ekrem M Ayhan, BS
908-619-5381
ayhane@stanford.edu
Stanford University
Interventions
  • Behavioral: Dietary Intervention Mediterranean Low Carbohydrate Diet — Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
  • Behavioral: Dietary Intervention Standard Low Carbohydrate Diet — Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
  • Behavioral: Dietary Intervention Standard Low Fat Diet — Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
Study Locations (1 sites)
Stanford University, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Age 35-65 * BMI 25-35 kg/m2 * Stable body weight * Nondiabetic Exclusion Criteria: Patients with; * diabetes * major organ disease * history of liposuction or bariatric surgery * active eating or psychiatric disorder * pregnancy or lactation, heavy alcohol use * recent change in weight (over the past 12 weeks) * use of weight loss medication, statins, or oral steroids Clinical screening exclusions; * hematocrit \< 33% * fasting glucose \>/= 126 mg/dL * blood pressure \>160/100 mmHg
Conditions Type 2 Diabetes, Overweight, Obesity
Phase NA
Enrollment 146
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to examine the effect plant-based diet, with a partial replacement of animal protein by plant protein, in blood sugar levels and other health risks of people with type 2 diabetes and excessive weight. The plant-based diet will be compared to a standard healthy diet according to guidelines for people with diabetes. Participants will follow a plant-based or a standard healthy diet for 24 weeks and will maintain their habitual levels of physical activity.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Control Diet — Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 50% of energy from carbohydrates, prioritizing those with low glycemic index; 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
  • Behavioral: Plant-based Diet — Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 50% of energy from carbohydrates, prioritizing those with a low glycemic index; 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.

Primary Outcomes

  • Change in Glycated Hemoglobin (baseline, 12 and 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-11-01
Completion: 2027-12-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 146 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital de Clinicas de Porto Alegre
Collaborators: Conselho Nacional de Desenvolvimento Científico e Tecnológico
Principal Investigators:
  • Fernando Gerchman, PhD (PRINCIPAL_INVESTIGATOR) - Hospital de Clinicas de Porto Alegre
Contact Information
Study Contact:
Fernando Gerchman, PhD
+555133596246
fgerchman@hcpa.edu.br
Fernando Gerchman, PhD
55 51 33598127
fgerchman@hcpa.edu.br
Hospital de Clínicas de Porto Alegre
Interventions
  • Behavioral: Control Diet — Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 50% of energy from carbohydrates, prioritizing those with low glycemic index; 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
  • Behavioral: Plant-based Diet — Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 50% of energy from carbohydrates, prioritizing those with a low glycemic index; 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
Study Locations (1 sites)
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul Brazil
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 and ≤65 years old) * Diagnosis of Type 2 Diabetes; * Glycated hemoglobin from 7% to 11%; * Overweight or obesity (BMI ≥25 kg/m² and \<40 kg/m²); * Use of any hypoglycemic and insulin; * Stable weight (maximum variation of approximately 5%) for at least 12 weeks before screening; * Not having undergone dietary intervention in the last 6 months; * Have the ability to understand and be able to adhere to intervention proposals; * Able and willing to provide an informed consent form for written and to comply with the requirements of the study protocol; Exclusion Criteria: * Type 1 diabetes mellitus; * Retinopathy with vision deficit that limits the activities proposed in the interventions; * Chronic kidney disease with estimated glomerular filtration \< 30 mL/min per 1.73m²; * Liver failure, chronic viral hepatitis; * Grade III or IV heart failure * Active or progressive neurodegenerative disease; * Prior stroke that has caused sequelae; * Use of medications that affect glucose metabolism (e.g. corticosteroids or immunosuppressants) or cause weight loss; * Chronic treatment with oral or parenteral corticosteroids (\>7 days consecutive treatment) within 4 weeks prior to screening; * Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion, liraglutide, semaglutide) within the last 12 weeks before screening; * Treatment with thyroid hormone that was not maintained at a stable dose in last 12 weeks before screening; * History of active substance abuse (including alcohol) within the last year; * Thyroid Stimulating Hormone (TSH) outside the normal range; * Fasting triglycerides ≥ 600 mg/dL; * Tumor diagnosed and/or treated (except basal cell skin cancer, carcinoma in situ of the cervix, or prostate cancer in situ) within the last 5 years; * Severe psychiatric illness; * Predisposition or diagnosis of eating disorders; * Women who are pregnant, intend to become pregnant during the study period, or who are currently breastfeeding; * Hyperglycemia characterized by acute symptoms: polyuria, polydipsia and/or weight loss in the last 3 months; * Metabolic and acute complications of diabetes such as ketoacidosis or hyperosmolar coma; * Potentially unreliable patients and those deemed by the investigator to be unsuitable for the study; * Night workers who work after 10pm; * Being on a vegetarian, vegan or flexitarian diet at the time of recruitment; * Having undergone bariatric surgery; * Carriers of the human immunodeficiency virus (HIV); * Any other medical condition/disorder that the investigators consider that are likely to: interfere with the patient's ability to complete the entire study period or participate in study activities; * Participants who require any treatment that could affect the interpretation, reliability or safety of data during the study intervention.
Conditions Obesity, Type 2 Diabetes
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Bariatric surgery + goal directed medical therapy — Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
  • Procedure: Bariatric surgery — Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner

Primary Outcomes

  • Proportion of patients in each group reaching the composite end point (5 years)
  • Proportion of patients reaching end point for glycemic control (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-04-01
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Imperial College London
Contact Information
Study Contact:
Alexander Miras, MRCP
: +44 (0)20 8383 3242
a.miras@nhs.net
Carel le Roux, PhD
University College Dublin
Interventions
  • Procedure: Bariatric surgery + goal directed medical therapy — Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
  • Procedure: Bariatric surgery — Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
Study Locations (1 sites)
University College Dublin, Dublin, Ireland
Eligibility Criteria
Inclusion Criteria: * eligible for bariatric surgery according to NICE guidelines (GC 189) * Type 2 diabetes mellitus * BMI \>30kg/m2 Exclusion Criteria: * Recent hospitalisation in the past 30 days * Recurrent hypoglycaemic episodes * Recurrent hypotensive episodes * Contraindications to bariatric surgery * Previous bariatric surgery * Current pregnancy * Breastfeeding
Conditions Gastric Cancer, Diabetes Mellitus, Type ...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multi-center, randomized controlled trial to compare Billroth II reconstruction versus conventional Roux-en-Y reconstruction versus long limb Roux-en-Y reconstruction for glycemic control in patients with concurrent type 2 diabetes and gastric cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Long limb Roux-en-Y reconstruction after subtotal gastrectomy — The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
  • Procedure: Conventional Roux-en-Y reconstruction after subtotal gastrectomy — The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
  • Procedure: Billroth II reconstruction after subtotal gastrectomy — The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)

Primary Outcomes

  • The success rate of biochemical improvement of diabetes as measured by HbA1c < 6.5% (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-12-01
Completion: 2027-12
Eligibility
Age: 20 Years – 69 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Korea University Anam Hospital
Collaborators: Korea University Ansan Hospital, Korea University Guro Hospital, Chonnam National University Hospital, Kyung Hee University Hospital at Gangdong, Ajou University
Principal Investigators:
  • Sungsoo Park, MD, PhD (PRINCIPAL_INVESTIGATOR) - Korea University Anam Hospital
Contact Information
Study Contact:
Sungsoo Park, MD, PhD
+82 2 920 6772
kugspss@korea.ac.kr
Yeongkeun Kwon, MD, PhD
+82 2 920 6772
kukwon@korea.ac.kr
Sungsoo Park, MD, PhD
+82 2 920 6772
kugspss@korea.ac.kr
Korea University Anam Hospital
Interventions
  • Procedure: Long limb Roux-en-Y reconstruction after subtotal gastrectomy — The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
  • Procedure: Conventional Roux-en-Y reconstruction after subtotal gastrectomy — The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
  • Procedure: Billroth II reconstruction after subtotal gastrectomy — The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
Study Locations (1 sites)
Korea University Anam Hospital, Seoul, 02841 South Korea
Eligibility Criteria
Inclusion Criteria: * Distal gastric adenocarcinoma diagnosed pathologically under preoperative endoscopic biopsy, and clinical stage I-II * Body mass index ≥ 23 kg/m2 * Type 2 diabetes and HbA1c ≥ 6.5% Exclusion Criteria: * Insulin usage for glycemic control at the time of screening evaluation * Prior gastrointestinal surgery including splenectomy, hepatobiliary and pancreatic surgery (except hemorrhoidectomy, herniorrhaphy, and appendectomy) * Abdominal, thoracic, pelvic and/or obstetric-gynecologic surgery within 3 months * Cardiovascular conditions including significant known CAD, uncompensated congestive heart failure, history of stroke, or uncontrolled hypertension. Subjects with CAD that have been successfully treated with CABG or PCI, and have no evidence of active ischemia are eligible * Kidney disease including renovascular hypertension, renal artery stenosis, or end-stage renal disease * Chronic liver disease including liver cirrhosis, alpha-1 antitrypsin deficiency * Gastrointestinal disorders including inflammatory bowel disease (Crohn's disease or ulcerative colitis) or any malabsorptive disorders * Psychiatric disorders including dementia, active psychosis, history of suicide attempts, alcohol or drug abuse within 12 months * Severe pulmonary disease defined as FEV1 \<50% of predicted value * Anemia defined as hemoglobin less than 8 in females and 10 in males * Malignancy within 5 years (except squamous cell and basal cell cancer of the skin). Subjects diagnosed with early or stage I cancer than have been successfully treated are eligible per investigator discretion * Frail elderly (Rockwood Clinical Frailty Scale ≥5) * Any condition or major illness that, in the investigator's judgement, places the subject at undue risk by participating in the study * Unable to understand the risks, realistic benefits and compliance requirements of each program * Use of investigational therapy or participation in any other clinical trial within 3 months * Geographic inaccessibility * Pregnancy